Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Astellas Pharma Inc    4503   JP3942400007

ASTELLAS PHARMA INC (4503)
Mes dernières consult.
Most popular
  Report  
 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (JPY)
Sales 2018 1 299 B
EBIT 2018 220 B
Net income 2018 179 B
Finance 2018 338 B
Yield 2018 2,28%
Sales 2019 1 294 B
EBIT 2019 249 B
Net income 2019 193 B
Finance 2019 435 B
Yield 2019 2,37%
P/E ratio 2018 17,28
P/E ratio 2019 16,31
EV / Sales2018 2,26x
EV / Sales2019 2,19x
Capitalization 3 273 B
More Financials
Company
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products.Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic... 
Sector
Pharmaceuticals
Calendar
04/26Earnings Release
More about the company
Surperformance© ratings of Astellas Pharma Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ASTELLAS PHARMA INC
04/21ASTELLAS PHARMA : sells certain U.S. research facilities to Gilead
AQ
04/19ASTELLAS PHARMA : Findings on Immunoglobulins Discussed by Investigators at Aste..
AQ
04/16ACTINIUM PHARMACEUTICALS : to Showcase Capabilities of its AWE Technology Platfo..
AQ
04/12ASTELLAS PHARMA : Named "Outstanding Employer" for Supporting Employees with Mil..
AQ
04/12ASTELLAS PHARMA : New Colitis Data Have Been Reported by Investigators at Astell..
AQ
04/05SEATTLE GENETICS : and Astellas Receive FDA Breakthrough Therapy Designation for..
AQ
04/05ASTELLAS PHARMA : Studies from Astellas Pharma in the Area of Nephropathy Descri..
AQ
04/03ASTELLAS PHARMA : to Participate in 'Neglected Tropical Diseases Drug Discovery ..
AQ
04/02ASTELLAS PHARMA : Announces Personnel Change
AQ
03/30ACTINIUM PHARMACEUTICALS : Announces Collaborative Research Partnership with Ast..
AQ
More news
Sector news : Pharmaceuticals - NEC
04/21TAKEDA PHARMACEUTICAL : Keeps Courting Shire -- WSJ
DJ
04/20GRAIN HIGHLIGHTS : Top Stories of the Day
DJ
04/20Japan's Takeda sweetens $62 billion Shire offer
RE
04/20SHIRE PLC SHIRE PLC : Statement Re Proposal From -2-
DJ
04/20SHIRE PLC SHIRE PLC : Statement Re Proposal From Takeda Pharmaceutical Company L..
DJ
More sector news : Pharmaceuticals - NEC
Latest Tweets
04/19Astellas sells certain U.S. research facilities to Gilead  
04/19Astellas Announces Sale of Certain Agensys Research Facilities to Kite, a Gil.. 
04/19$GILD: Gilead Sciences: Astellas (ALPMY) announces sale of certain Agensys re.. 
04/19BRIEF-Astellas Announces Sale Of Certain Agensys Research Facilities To Kite,.. 
04/17#2 Joining a global M&A spree, Astellas reserves $2B for a spate of new b..
7
More tweets
Qtime:27
News from SeekingAlpha
04/20Key events next week - healthcare 
04/19Astellas sells certain U.S. research facilities to Gilead 
03/283 THINGS IN BIOTECH, MARCH 27 : Roche Rips, Loxo Rolls, Astellas Rams 
03/26Seattle Genetics' enfortumab vedotin a Breakthrough Therapy for urothelial ca.. 
03/193 THINGS IN BIOTECH, MARCH 18 : Exelixis Lives, Astellas Digs Deeper, Alexion Eq.. 
Chart ASTELLAS PHARMA INC
Duration : Period :
Astellas Pharma Inc Technical Analysis Chart | 4503 | JP3942400007 | 4-Traders
Technical analysis trends ASTELLAS PHARMA INC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 1 625  JPY
Spread / Average Target 2,7%
EPS Revisions
Managers
NameTitle
Kenji Yasukawa President, Chief Executive Officer & Director
Yoshihiko Hatanaka Chairman
Chikashi Takeda Chief Financial Officer
Mitsunori Matsuda Senior Executive Officer & President-Technology
Roderick Christmon Executive Director-Medical & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTELLAS PHARMA INC9.10%30 402
JOHNSON & JOHNSON-9.35%339 783
PFIZER1.13%217 897
NOVARTIS-7.67%204 972
ROCHE HOLDING LTD.-12.52%191 890
MERCK AND COMPANY4.55%158 571